← Back

Sirio Pharma

Sirio Pharma Co., Ltd. is a contract manufacturer serving the dietary supplement industry in China, the United States, Europe, and other international markets. It develops and manufactures softgel dietary supplements, vegetarian softgels, nutritious gummies, liquids, probiotic balls, tablets, powders, capsules, and functional beverages. These products target areas such as beauty and wellness, gut health, bone and joint health, immune and fertility support, cardiovascular and metabolic health, and healthy ageing. The company also provides formulation, technical and research and development support, and primary and final packaging services. Founded in 1993, it is headquartered in Shantou, China.

Country
Price · split & dividend adjusted
News & notes moving 300791.CS
ChinaUnited StatesThailandAustraliaNew Zealand
300791.CS5

Sirio Pharma H1 revenue hits 2.052 billion yuan as global operating capabilities continue to improve

Sirio Pharma disclosed its 2026 semi-annual report, with first-half operating revenue reaching 2.052 billion yuan, up 0.51 percent year on year. By region, China revenue was 802 million yuan, down 2.02 percent year on year, while gross margin improved by 0.73 percentage points. Europe revenue was 402 million yuan, up 11.74 percent year on year, with gross margin up 1.74 percentage points. Asia-Pacific and other regions revenue was 195 million yuan, up 86.79 percent year on year, driven by deeper cooperation with clients in Australia and New Zealand and higher softgel volumes. Americas revenue was 654 million yuan, down 13.93 percent year on year, mainly affected by US tariff policy, though gross margin improved by 2.42 percentage points. The company has completed the sale of core assets in its personal care business to focus on its core nutrition and health operations. The second gummy production line at its US plant has begun operations, and construction of its Thailand production base is advancing.
300791.CS · Capital · Neutral H1 revenue up 0.51% with mixed regional performance; US tariffs hurt Americas revenue but margins improved, and asset sale focuses on core business.
Read original ↗
证券时报·36dRead more →
ChinaUnited States
300791.CS▲

Multiple A-share companies announce receipt of US tariff refunds

Recently, multiple A-share listed companies have announced receipt of US tariff refunds. Hanshow Technology's wholly-owned subsidiary in the United States has cumulatively received US tariff and interest refunds totaling 23.1064 million US dollars, equivalent to approximately 157 million yuan. After withholding, the impact on the company's 2026 net profit is approximately 71.1716 million yuan, accounting for 15.75% of the most recent audited net profit. Leyard's consolidated subsidiaries have cumulatively received US tariff and interest refunds totaling 16.5598 million US dollars, equivalent to approximately 112 million yuan. The specific impact on 2026 performance remains to be confirmed. Sirio Pharma's overseas subsidiaries have cumulatively received tariff and interest refunds totaling 11.7029 million US dollars, equivalent to approximately 79.4436 million yuan. Rongjie Health's controlled subsidiaries have cumulatively received 7.252 million US dollars, with an expected impact on the company's net profit attributable to the parent of 17.9599 million yuan, accounting for 24% of the most recent audited net profit. Shanghai Jahwa's wholly-owned overseas subsidiary has cumulatively received tariff and interest refunds of 4.6636 million US dollars, equivalent to approximately 32.322 million yuan, accounting for 12.08% of the company's most recent audited net profit. CFMOTO's wholly-owned subsidiary has cumulatively received US tariff and interest refunds of 38.6079 million US dollars, equivalent to 262 million yuan, with an expected impact on 2026 net profit of approximately 183 million yuan, accounting for 10.95% of the most recent audited net profit. Healthcare Co., Ltd.'s consolidated subsidiaries have cumulatively received US tariff refunds of 2.1324 million US dollars, equivalent to approximately 14.4764 million yuan, to be included in 2026 current profit or loss.
301275.CS · Tariff · Positive US tariff refunds received by subsidiary, boosting net profit.
603129.CG · Tariff · Positive Received US tariff refunds of $38.61M, expected to boost 2026 net profit by ~10.95%
300296.CS · Tariff · Positive Received US tariff refunds of $16.56M, positive impact on 2026 performance
300791.CS · Tariff · Positive Received US tariff refunds of $11.70M, positive impact on earnings
600315.CG · Tariff · Positive Received US tariff refunds of $4.66M, boosting net profit by 12.08%
603313.CG · Tariff · Positive Received US tariff refunds of $2.13M, positive impact on earnings
Read original ↗
证券时报·47dRead more →
United StatesChina
300791.CS▲2

Sirio Pharma receives US tariff refund of about 79.44 million yuan

Sirio Pharma announced that its wholly-owned overseas subsidiary SN and controlled subsidiary SNC recently received a refund from US Customs and Border Protection, after the US Supreme Court ruled that the reciprocal tariffs imposed under IEEPA lacked statutory authority and the collected tariffs must be returned. To date, the cumulative refund of tariffs and interest totals 11.7029 million US dollars, equivalent to about 79.4436 million yuan. This refund does not require retrospective adjustment of prior financial statements. Part of the amount needs to be allocated through negotiation with customers, and the specific impact is yet to be confirmed.
300791.CS · Regulation · Positive US Supreme Court ruling invalidates tariffs, leading to refund for Sirio Pharma.
Read original ↗
每日经济新闻·53dRead more →